Chambers Rebecca 4

What Happened

• Rebecca Chambers, a director of Alamar Biosciences (ALMR), had paired Form 4 entries on 2026-04-20 showing a disposition of 140,612 derivative shares at $0.00 and an acquisition of 140,612 shares at $0.00. Both entries are coded "J" (other acquisition/disposition) and involve derivative securities.
• The filing indicates this was a non-cash reclassification tied to the company’s IPO: each Class B share was reclassified into one share of Common Stock immediately prior to the IPO (footnote F1). This is not an open-market purchase or sale and has no cash value.

Key Details

• Transaction date: 2026-04-20; Price: $0.00 for both the disposition and acquisition entries; Shares: 140,612 (disposed) / 140,612 (acquired).
• Transaction code J: typically used for conversions/reclassifications or other non-standard transfers.
• Shares owned after the transaction: not specified in the provided excerpt of the filing (check the full Form 4 for holdings after the reclassification).
• Footnote F1: Class B Common Stock reclassified 1-for-1 into Common Stock immediately before the IPO.
• Footnote F2: Describes a separate option vesting schedule (25% on Jan 15, 2027, then 1/48th monthly), indicating some option-based holdings vest over time.
• Filing timeliness: Reported with transaction and filing date of 2026-04-20 (appears timely).

Context

• This was a corporate reclassification related to the IPO rather than a market trade; zero-dollar entries reflect conversion, not a sale or purchase that reveals market sentiment.
• For retail investors: such reclassifications are administrative and do not directly signal buying or selling intent. The vesting note (F2) signals some option-derived shares are subject to future vesting conditions.